Skip to main content

Table 1 Characteristics of 3910 individuals initiating HAART at Themba Lethu Clinical by baseline dose of stavudine

From: Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa

Baseline characteristic

Dose of stavudine

 

40 mg

n = 2445

30 mg

n = 1465

Weight†

67.0 (62.8-74.0)

68.1 (63.6-75.6)

Age†

37 (32-43)

38 (33-44)

Male gender

1017(41.6)

628 (42.9)

African ethnicity

2,348 (96.0)

1,416 (96.7)

Employed

1,130 (46.2)

855 (58.4)

Tuberculosis

364 (14.9)

155 (10.6)

Haemoglobin (low)

823 (35.0)

433 (29.8)

WHO stage III or IV

956 (39.1)

356 (24.3)

CD4 count (cells/mm3)†

97 (39-163)

137 (66-192)

Efavirenz-based HAART

2203 (90.1)

1296 (88.5)

Nevirapine-based HAART

193 (7.9)

116 (7.9)

  1. All figures expressed as count (%) unless noted. † Expressed as median (interquartile range)